On Thursday, Shares of International Game Technology Ordinary Shares (NYSE:IGT), added -3.67% and closed at $27.81 in the last trading session. The last trading range of the stock ranges between $27.81 and $29.07. International Game Technology PLC (“IGT”) (IGT), the world’s leading end-to-end gaming Company, was recently recognized by the CDP (formerly the Carbon Disclosure Project) 2016 Climate Change Program for its commitment and actions fighting climate change. As part of the recognition, IGT was noted for effectively reducing emissions, indicating advanced environmental stewardship.
IGT scored higher than the industry sector average, and the overall average score of all responding companies. This acknowledgment signals that IGT is measuring and managing its environmental impact in line with the Paris Agreement aims set in 2015 to limit global warming. This is also IGT’s first recognition in Climate Change Administration since becoming one Company after legacy GTECH and legacy IGT merged in 2015.
Sunoco LP (NYSE:SUN), dropped -7.89% and closed at $24.98 in the last trading session. The last trading range of the stock ranges between $24.96 and $28.00. The company’s Market capitalization is $2.95 Billion with the total Outstanding Shares of 49.59 million. Energy Transfer Equity, L.P. (ETE) (“ETE” or the “Partnership”) recently stated financial results for the quarter ended September 30, 2016.
ETE’s net income attributable to partners was $209 million for the three months ended September 30, 2016 contrast to $293 million for the three months ended September 30, 2015. Distributable Cash Flow, as adjusted, for the three months ended September 30, 2016 was $281 million contrast to $325 million for the three months ended September 30, 2015. The decreases in net income attributable to partners and Distributable Cash Flow, as adjusted, were mainly driven by an $85 million reduction in incentive distributions from ETP. As formerly stated, ETE has agreed to a reduction in incentive distributions from ETP in the aggregate amount of $720 million over a period of seven quarters, starting the quarter ended June 30, 2016.
Curis, Inc. (NASDAQ:CRIS), jumped 2.86% and closed at $3.24 in the last trading session. The last trading range of the stock ranges between $3.03 and $3.49. During the 52-week trading session the minimum price at which share price traded, registered at $1.25 and reached to max level of $3.49. Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for advanced lymphomas and multiple myeloma. It also develops CUDC-427 that has accomplished Phase I clinical trials for advanced solid tumor and lymphomas; CA-170, which is in preclinical stage for the treatment of cancer; CA-4948, which is in preclinical stage for the treatment of hematologic cancers; Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma (BCC); and CUDC-305 drug candidate that has accomplished Phase I clinical trials for the treatment of cancers. The company has partnershipagreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and partnershipand license agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge.